Evidence map›Paper›PMID 27631260›Full record

Observational studyMedicine2016

Cross-sectional study of virological failure and multinucleoside reverse transcriptase inhibitor resistance at 12 months of antiretroviral therapy in Western India.

Santosh K Karade, Manisha V Ghate, Devidas N Chaturbhuj, Dileep B Kadam, Subramanian Shankar, Nitin Gaikwad, Shraddha Gurav, Rajneesh Joshi, Suvarna S Sane, Smita S Kulkarni and 4 more

Open access · goldAbstract readObservational Study
In one paragraph

Observational study in Medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Ending AIDS: The 90-90-90 strategy.Medical journal, Armed Forces India · 2017
    Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 6 institutions in 4 countries.

Santosh K KaradeHIV Drug Resistance Laboratory Department of Clinical Sciences, National AIDS Research Institute Department of Medicine, BJ Medical College and Sasoon General Hospital, Pune Department of Medicine, Command Hospital (Air Force), Bangalore Department of Tuberculosis and Chest Diseases, YCM Hospital Department of Epidemiology and Biostatistics Department of Molecular Virology Department of Immunology, National AIDS Research Institute, Pune Department of AIDS Control, National AIDS Control Organization, New Delhi, India.
Manisha V Ghate
Devidas N Chaturbhuj
Dileep B Kadam
Subramanian Shankar
Nitin Gaikwad
Shraddha Gurav
Rajneesh Joshi
Suvarna S Sane
Smita S Kulkarni
Swarali N Kurle
Ramesh S Paranjape
Bharat B Rewari
Raman R Gangakhedkar
CNR de la Résistance aux Antibiotiques · FRNational AIDS Research Institute · INB. J. Medical College & Sassoon Hospital · INChest Diseases Hospital · KWCommand Hospital Air Force · INNational AIDS Control Organisation · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The free antiretroviral therapy (ART) program in India has scaled up to register second largest number of people living with HIV/AIDS across the globe. To assess the effectiveness of current first-line regimen we estimated virological suppression on completion of 1 year of ART. The study describes the correlates of virological failure (VF) and multinucleoside reverse transcriptase inhibitor (NRTI) drug resistance mutations (DRMs).In this cross-sectional study conducted between June and August 2014, consecutive adults from 4 State sponsored ART clinics of western India were recruited for plasma viral load screening at 12 ± 2 months of ART initiation. Individuals with plasma viral load >1000 copies/mL were selected for HIV drug resistance (HIVDR) genotyping. Logistic regression analyses were performed to assess factors associated with VF and multi-NRTI resistance mutations. Criteria adopted for multi-NRTI resistance mutation were either presence of K65R or 3 or more thymidine analog mutations (TAMs) or presence of M184V along with 2 TAMs.Of the 844 study participants, virological suppression at 1 year was achieved in 87.7% of individuals. Factors significantly associated with VF (P < 0.005) were 12 months CD4 count of ≤100 cells/μL (adjusted OR -7.11), low reported adherence (adjusted OR -4.44), and those living without any partner (adjusted OR -1.98). In patients with VF, the prevalence of non-nucleoside reverse transcriptase inhibitor (NNRTI) DRM (78.75%) were higher as compared to NRTI (58.75%). Multi-NRTI DRMs were present in 32.5% of sequences and were significantly associated with CD4 count of ≤100 cells/μL at baseline (adjusted OR -13.00) and TDF-based failing regimen (adjusted OR -20.43). Additionally, low reported adherence was negatively associated with multi-NRTI resistance (adjusted OR -0.11, P = 0.015). K65R mutation was significantly associated with tenofovir (TDF)-based failing regimen (P < 0.001).The study supports early linkage of HIV-infected individuals to the program for ART initiation, adherence improvement, and introduction of viral load monitoring. With recent introduction of TDF-based regimen, the emergence of K65R needs to be monitored closely among HIV-1 subtype C-infected Indian population.

Indexed as

Reverse Transcriptase InhibitorsAdultCross-Sectional StudiesDrug Resistance, ViralFemaleGenotyping TechniquesHIV-1HIV InfectionsHumansMaleMiddle AgedMutationTreatment FailureReverse Transcriptase Inhibitors

Identifiers

PMID27631260
PMCPMC5402603
OpenAlexW2519640715

What OpenQuestion holds

Textmetadata
LicenceCC BY-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.